This study is comparing two types of insulin, insulin glargine and insulin NPH, for managing diabetes during pregnancy. Insulin NPH has been a standard treatment, while insulin glargine is commonly used outside of pregnancy and has less research specifically for pregnant individuals. We want to see if insulin glargine is as effective as insulin NPH in preventing low blood sugar (hypoglycemia) in pregnant individuals with Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus who need insulin. You may be able to join if you are at least 18 years old, need to start insulin for diabetes in pregnancy before 34 weeks, and have established prenatal care. The study is currently recruiting 160 participants.

Study design

This is an open-label, randomized study where participants will be assigned to receive either insulin NPH or insulin glargine. It aims to see if glargine is not worse than NPH.

What's involved

You would monitor your blood sugar four times a day, log your values, and continue routine prenatal care and ultrasounds. You will also receive insulin teaching and nutrition education.

Compensation

Not stated in the trial record.

Follow-up

Your hypoglycemia will be measured from when you start insulin therapy until delivery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.